Stay updated with breaking news from Opgen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wall Street analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to report $20.90 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Precigen’s earnings, with the lowest sales estimate coming in at $17.30 million and the highest estimate coming in at $24.50 million. Precigen posted sales of […]
Brokerages expect that Precigen, Inc. (NYSE:PGEN – Get Rating) will announce earnings of ($0.14) per share for the current quarter, Zacks reports. Two analysts have made estimates for Precigen’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.13). Precigen posted earnings of ($0.11) per share in […]
OpGen (NASDAQ:OPGN – Get Rating) released its quarterly earnings results on Tuesday. The medical research company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.19), MarketWatch Earnings reports. OpGen had a negative net margin of 829.32% and a negative return on equity of 82.94%. During the same […]
PFG Advisors bought a new position in Precigen, Inc. (NASDAQ:PGEN – Get Rating) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,083 shares of the biotechnology company’s stock, valued at approximately $37,000. A number of other hedge funds also recently […]
Precigen, Inc. (NASDAQ:PGEN – Get Rating) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 22,870,000 shares, an increase of 26.2% from the January 31st total of 18,120,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently […]